NewAmsterdam Pharma (Frazier Lifesciences Acquisition) ^{Priced, Nasdaq: NAMS}

We are a newly organized blank check company incorporated on October 7, 2020. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector. Our sponsor, Frazier Lifesciences Sponsor LLC, is an affiliate of Frazier Healthcare Partners, founded in 1991 as one of the first healthcare dedicated investment firms, with nearly $4.8 billion raised across 12 institutional funds. Our management team is led by Jamie Topper, M.D., Ph.D., Managing General Partner at Frazier who will serve as Chairman of the Board of Directors and Chief Executive Officer; David Topper, Senior Advisor at Frazier who will serve as Chief Financial Officer; Gordon Empey, Frazier Life Sciences Partner and General Counsel, who will serve as Vice President and General Counsel; and Max M. Nowicki, Senior Associate at Frazier who will serve as Vice President, Acquisitions. Our management team and board members have extensive experience in clinical medicine, drug development, regulatory strategy, and operational and management leadership within academia as well as the healthcare and financial industries.